Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer

A. Paradiso, V. Lorusso, S. Tommasi, F. Schittulli, E. Maiello, M. De Lena

Research output: Contribution to journalArticle


The relationship between cell kinetics and hormonal status and the relevance of the cell kinetic variable on success of hormonetherapy in estrogen receptor positive (ER+) breast tumors were analyzed in patients with advanced disease. Cell kinetics were evaluated as in vitro3H-thymidine labeling index (LI), and estrogen receptor (ER) and progesterone receptor (PgR) with the dextran-coated charcoal technique. The analyses performed on primary tumor or soft tissue metastases from 52 patients showed a general association between the presence of hormone receptors and low proliferative activity, or the absence of receptors and high proliferative activity (ER and L.I.: p>0.05; PgR and L.I.: p = 0.05). However, hormonal status and cell kinetic status were unrelated in about 40% of the cases. Clinical response to additive hormonotherapy was analyzed in relation to pretreatment LI in 29 patients with ER+ tumors. Time to reach maximum response was significantly longer in slow than in fast proliferating tumors, but complete remission was reached in 88% of slow proliferating tumors compared to only 46% of fast proliferating tumors. These preliminary results show that ER+ fast proliferating tumors largely escape hormonal control, and if confirmed on larger series, could identify cell kinetics as an important tool to select patients who will benefit from hormonal treatment.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalBreast Cancer Research and Treatment
Issue number1
Publication statusPublished - Apr 1988


  • breast cancer
  • cell kinetics
  • hormone receptors
  • hormonetherapy
  • prognostic factors
  • thymidine labelling index

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this